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Large outbreaks of Q fever in the Netherlands from 
2007 to 2009 were monitored using notification data 
of acute clinical Q fever. However, the notification sys-
tem provides no information on infections that remain 
subclinical or for which no medical attention is sought. 
The present study was carried out immediately after 
the peak of the 2009 outbreak to estimate the ratio 
between Coxiella burnetii infections and Q fever noti-
fications. In 23 postcode areas in the high-incidence 
area, notification rates were compared with serocon-
version rates in blood donors from whom serial sam-
ples were available. This resulted in a ratio of one Q 
fever notification to 12.6 incident infections of C. bur-
netii. This ratio is time and place specific and is based 
on a small number of seroconversions, but is the best 
available factor for estimating the total number of 
infections. In addition, as subclinical C. burnetii infec-
tion may lead to chronic Q fever, the ratio can be used 
to estimate the expected number of chronic Q fever 
patients in the coming years and as input for cost–
benefit analyses of screening options.
Introduction
Q fever is a zoonosis caused by Coxiella burnetii. The 
bacterium has a worldwide distribution in domesti-
cated and wild animals, but transmission to humans 
is mostly associated with sheep and goats [1]. Most 
patients with Q fever recover after mild febrile illness; 
others may experience pneumonia, hepatitis or, more 
rarely, myocarditis or central nervous system complica-
tions [2]. Because the clinical presentation of acute Q 
fever is rather non-specific, laboratory confirmation is 
essential. C.  burnetii has two antigenic phases (I and 
II) and with serological assays, IgM II, IgG II, IgM I and 
IgG I antibodies are used to distinguish between acute 
infection and chronic infection.
From 2007 to 2009, the Netherlands faced large sea-
sonal outbreaks of Q fever, with the highest peak 
in 2009 [3]. Surveillance of Q fever is mandatory in 
European Union (EU) countries. In 2009, a total of 370 
Q fever cases were reported in 24 EU countries, apart 
from the 2,317 cases from the 2009 outbreak in the 
Netherlands [4]. The low number of notifications is in 
contrast to results from seroprevalence studies, which 
suggest that 2–10% of the general population in EU 
countries have previously been infected with C.  bur-
netii [1]. People with a C. burnetii infection will only be 
notified as Q fever cases to the national public health 
authorities if: (i) they have symptoms; (ii) they seek 
medical attention; (iii) have been tested with a Q fever 
diagnostic laboratory test; (iv) the test is sensitive and 
shows a positive result; (v) the physician or laboratory 
notifies the case to the local public health authorities; 
and (vi) the local public health authorities confirm that 
the notification criteria are fulfilled and reports the 
case to the national public health authorities. Each of 
these steps has an influence on the difference between 
the true number of infections and the number of noti-
fications. However, little is known about the relative 
importance of the various steps.
An estimate much cited in the international literature 
is that 40% of C.  burnetii infections are symptomatic 
[2,5]. However, this estimate is based on just one origi-
nal study, from an outbreak in Switzerland in 1983, in 
which 191 (46%) of 415 serologically confirmed cases 
were symptomatic [6]. Hardly any information is avail-
able on the health-seeking behaviour of symptomatic 
patients. Symptomatic C.  burnetii infection (Q fever) 
may resemble influenza-like illness, for which only 
an estimated 20% in the Netherlands seek medical 
care [7] and for which most general practitioners will 
not request a laboratory test. Low sensitivity of the 
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laboratory test and failure to report a diagnosis of Q 
fever are probably of minor importance during a period 
in which there is a high number of incident cases and 
both the physician and laboratory are legally required 
to notify cases.
Before the recent Q fever epidemic in the Netherlands, 
the seroprevalence of 2.4% in the general population 
was relatively low in comparison with that in other 
countries [8]. The epidemic resulted in an unprece-
dented number of 3,522 laboratory-confirmed Q fever 
cases notified from 2007 to 2009 [9]. Policy decisions 
on veterinary interventions were to a large extent 
based on close monitoring of these human Q fever noti-
fications. With the declining number of Q fever notifica-
tions in 2010, attention has shifted to the increasing 
number of patients with long-term effects of acute Q 
fever, especially Q fever fatigue syndrome and chronic 
Q fever. The number of asymptomatic infections is 
relevant in this context, because asymptomatic infec-
tions can also lead to chronic Q fever, mostly in people 
with risk factors such as cardiac valve disease, aneu-
rysm, vascular graft or pregnancy [10]. Knowing the 
total number of persons infected, including those with 
asymptomatic infections, would allow better estimates 
of the expected number of chronic disease cases. There 
are also other remaining public health policy ques-
tions that pertain to screening of blood, semen, tissue 
and organ donors, pregnant women and patients with 
cardiac valve or vascular disease for asymptomatic 
infection. For these reasons, having an estimate of 
the number of infections is important for public health 
policy. The present study therefore focuses on the 
ratio of the incidence of C. burnetii infection to that of 
notified Q fever cases during the 2009 outbreak in the 
Netherlands by relating the number of blood donors 
with seroconversion to figures from the national infec-
tious diseases notification system.
Methods
Notifications
We used data on notifications for 1 June 2009 to 31 
January 2010 from the 23 postcode areas in the south 
of the Netherlands that had the highest incidence of 
notified Q fever cases between weeks 26 and 37 of 
2009 (22 June to 13 September) [11]. According to Dutch 
legislation, the attending physician and the head of the 
medical microbiology laboratory must notify any diag-
nosis of acute Q fever to the municipal health service. 
Of the 23 postcode areas, 21 were under the municipal 
health service ‘Hart voor Brabant’ and two were under 
a neighbouring municipal health service. The munici-
pal health services interviewed the notified patients 
and entered information on those who fulfilled the 
notification criteria into the national infectious dis-
eases surveillance database. Notification criteria of 
acute Q fever were a clinical presentation with fever or 
pneumonia or hepatitis, in combination with a positive 
laboratory result indicating acute C. burnetii infection. 
The laboratory criteria were a fourfold IgG titre rise or 
more measured by immunofluorescence assay (IFA), 
enzyme-linked immunosorbent assay (ELISA) or com-
plement fixation test, a positive IgM phase II antibody 
test or detection by polymerase chain reaction (PCR) of 
C. burnetii DNA in blood or respiratory material.
Blood donors
Sanquin Blood Supply Foundation is the only organisa-
tion in the Netherlands authorised to manage the sup-
ply of blood and blood products. To assess the safety 
of donated blood, samples of blood donations from 
people living in the most affected area were collected 
by Sanquin over a one-year period from 20 May 2009. 
From this collection, donations from people living in 
the 23 postcode areas with the highest incidence were 
tested for the presence of antibodies against C.  bur-
netii. Details of the study have been reported else-
where [11]. Briefly, serological data were generated of 
the 543 donors who donated more than once in the first 
eight months of the study (20 May 2009 to 15 January 
2010). The donor’s last donation was screened for the 
presence of IgG antibodies to phase II of C.  burnetii 
using a commercial ELISA (Serion, Clindia Benelux, the 
Netherlands). All ELISAs that gave borderline results 
(IgG levels of 20–30 international units (IU)/ml) or 
positive (>30 IU/ml) sera were confirmed by IFA (Focus 
Diagnostics, United States). An IgG II antibody titre 
of ≥1:64 was considered positive in the IFA. If the last 
donation tested positive, the donor’s previous dona-
tion was also tested in the same way.
The mean age of the 543 donors was 49.5 years (range: 
19–70 years) and 60.4% were male (n=328). Due to 
Sanquin privacy regulations, information on age and 
sex at the individual donor level was not available.
Data analysis
The incidence of infection was calculated by dividing 
the number of blood donors with seroconversion by 
the person-time of follow-up. As population figures by 
postcode area were available by five-year age groups 
[12], we used the age range 20–69 years instead of 
19–70 years.
The incidence of notified acute Q fever cases was cal-
culated by dividing the number of notifications of per-
sons aged 20–69 years with a date of symptom onset 
between 1 June 2009 and 31 January 2010 by the total 
number of people aged 20–69 years living in the 23 
postcode areas on 1 January 2010 (n=55,715).
Results
Notifications
The number of acute Q fever notifications (all ages) in 
the 23 postcode areas was 75 in 2007, 323 in 2008 and 
570 in 2009 (Figure). There were 167 notifications of 
cases aged 20–69 years who had a date of symptom 
onset between 1 June 2009 and 31 January 2010.
 The mean age of the 167 notified cases was 45.6 years 
and 53.9% (n=90) were male. With a population size of 
55,715, the incidence of notified cases was 4.5 (95% 
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confidence interval (CI): 3.9–5.2) per 1,000 persons 
per year.
Infections
Of the 543 people who donated blood more than once 
during 20 May 2009 to 15 January 2010, 66 tested posi-
tive or borderline for C.  burnetii IgG antibodies in the 
last donation [11]. All 66 ELISA-reactive sera had a 
phase II IgG antibody titre ≥1:64 in the confirmatory 
IFA. The phase II IgG seroprevalence in the 23 postcode 
areas was therefore 12.2% (95% CI: 9.7–15.2). When 
the previous donation of the 66 seropositive donors 
was tested, 10 of the 66 sample pairs were identified 
as seroconversions for IgG phase II. In two of the 10 
donors, the seroconversion was from a weak antibody 
response to at least a fourfold higher titre in the IFA in 
the last donation; for the other eight donors, no anti-
bodies were detected at all in the previous donations.
The cumulative follow-up period for the 487 (543 minus 
56) donors without C.  burnetii IgG antibodies in the 
previous donation was 64,135 days. With 10 serocon-
versions observed, the C.  burnetii infection incidence 
was 56.9 (95% CI: 31.2–101.4) per 1,000 person-years. 
This point estimate translates into 2,113 (95% CI: 1,159–
3,766) new infections among those aged 19–70 years in 
the study area over the eight-month study period.
On the basis of the notifications and seroconversions, 
there was a ratio of one Q fever notification to 12.6 inci-
dent infections of C.  burnetii – i.e. 7.9% of the infec-
tions that occurred in the area were notified.
Discussion
The study provides an estimate of incidence of infec-
tion with C. burnetii in relation to incidence of notified 
acute Q fever cases. It suggests that the 3,522 acute Q 
fever cases that were notified in the Netherlands from 
2007 to 2009 correspond to more than 44,000 infec-
tions in the same period. This rough estimate is likely 
to be an underestimation as underreporting outside 
the high-incidence study area was probably higher. 
However, our study pertains to a particular time and 
area: the estimate for the entire epidemic is indicative 
only and should be interpreted with caution.
In the village where the first outbreak in 2007 occurred, 
443 inhabitants provided a blood sample, of which 73 
(16.5%) showed a recent infection [13]. Of these 73 peo-
ple, 48 had symptoms that could be attributed to Q 
fever. This suggests that 66% were symptomatic infec-
tions. However, the actual percentage of symptomatic 
infections is likely to be lower, as symptoms are non-
specific and could easily have been misclassified as Q 
fever-related.
Figure 
Notifications for acute Q fever in 23 postcode areas in the high-incidence area of the Netherlands, 2007–2010
The arrowed line indicates the study period for collection of notification data (1 June 2009 to 31 January 2010).
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Even if we accept the prevailing estimate from the inter-
national literature that 40% of C.  burnetii infections 
are symptomatic, it is clear that a large proportion of 
symptomatic cases do not seek medical attention or 
are not diagnosed as acute Q fever patients. It is a 
common finding that surveillance systems have low 
reporting efficiency for infectious diseases with mild 
or non-specific symptoms [14].
The proportion of infections that is not notified 
because patients do not seek medical attention or a 
diagnostic test is not requested, is neither fixed nor 
random, but is highly affected by certain factors, such 
as media attention or physicians’ awareness that a par-
ticular pathogen is circulating. At the time of study in 
the second half of 2009, awareness of Q fever among 
patients and general practitioners in this area was at 
a high level [15]. In combination with easy availability 
of diagnostic facilities in the area, we can expect that 
a larger proportion of symptomatic C.  burnetii infec-
tions were diagnosed as acute Q fever compared with 
areas with lower awareness and where laboratory tests 
for C. burnetii infection were not routinely available to 
general practitioners. Raoult et al. showed a high inci-
dence of Q fever around the French National Reference 
Centre for Rickettsial Diseases (in Marseille, France) 
[16], suggesting high levels of awareness and testing 
in this area. Conversely, in a low-incidence situation, 
the absolute number of cases that are not notified 
would be low, while the proportion of infections that 
is not notified could be high. This will especially be the 
case when the beginning of an outbreak passes largely 
unnoticed. This happened in 2007 in the Netherlands, 
when increasing numbers of pneumonia cases were 
first thought to be due to Mycoplasma pneumoniae 
infection. Retrospectively, a number of clusters of hos-
pital admissions for respiratory tract infections were 
identified that occurred in 2005 to 2007 – earlier than 
the recorded Q fever outbreaks – which could have 
been Q fever because there was a Q fever-affected 
farm nearby and there was no alternative explanation 
for the cluster [17].
A limitation of our study is that in general, healthy 
adult blood donors poorly represent the general popu-
lation. However, Q fever is an airborne infection, thus 
reducing biases caused by the comparison of donors 
with the general population [11]. The age and sex distri-
bution of the donors in the study population was very 
similar to those of the notified Q fever cases in the 
Netherlands (mean age of 50 years, 62% male) over the 
entire epidemic period from 2007 to 2009 [3]. We had 
no information on addresses of blood donors and could 
therefore not correct for possible differences between 
donors and notified Q fever patients in the proximity of 
their places of residence to infected farms.
The 12.2% seroprevalence among blood donors sug-
gests that approximately 6,800 people in the age 
group 20–69 years in the study area had been infected 
at the time of the study, i.e. after the 2007 and 2008 
outbreaks and half-way through the 2009 outbreak. 
This estimated number of prevalent cases seems low 
in comparison with the number of notifications and the 
estimated incident infections. It illustrates that in relat-
ing incidence to prevalence, other parameters have to 
be taken into account such as the decay rates of anti-
body titres.
In conclusion, our study suggests that during the peak 
of the epidemic in the Netherlands, every notification 
of clinical Q fever represented more than 12 infections 
with C.  burnetii. Despite uncertainties surrounding 
the clinical significance of asymptomatic seroconver-
sion, this ratio could be used as one factor to estimate 
the number of chronic Q fever patients that could be 
expected in the coming years and as input for cost–
benefit analyses of screening options.
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